Look up one drug

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Imitrex · DIN 02163764 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2007-06-06 Health Canada: Cancelled post market since 1998-07-30 · brand IMITREX - TAB 50MG · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50 MG · company Glaxo canada inc · schedule Prescription

DIN 02163764: Imitrex Raw flags: sec3=Y, sec3b=Y Item: 289200009; group id 545; item number 1473; lccId None; manufacturer id GSK Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163764 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19368

Interchangeable products

Apo-Sumatriptan · DIN 02268388 · $9.0650 Co Sumatriptan · DIN 02257890 · $9.0650 Jamp Sumatriptan · DIN 02545357 · $9.0650 Mylan-Sumatriptan · DIN 02268914 · $9.0650 PMS-Sumatriptan · DIN 02256436 · $9.0650 Ratio-Sumatriptan · DIN 02271583 · $9.0650 Sandoz Sumatriptan · DIN 02263025 · $9.0650 Sumatriptan · DIN 02286521 · $9.0650 Sumatriptan · DIN 02546035 · $9.0650

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Cancelled post market since 1998-07-30 — choose a marketed DIN from the same-category list.